Methods and systems of identifying an electrode or combination of electrodes of a multi-electrode device for pacing include selecting a first electrode or electrode combination as a first candidate; delivering a pacing pulse through the first candidate and determining a measurement based on sensed cardiac electrical activity resulting from the first candidate pacing; selecting a second candidate; delivering a pacing pulse through the second candidate and determining a measurement based on sensed cardiac electrical activity resulting from the second candidate pacing; comparing the measurement for the first and second candidates; and identifying the first or second candidate for pacing based on the comparison. The measurement may be one or more of activation time ΔTact, activation recovery interval (ari), a fractioned electrogram width, and a standard deviation of a fractioned electrogram feature.
|
1. A method of identifying an electrode or combination of electrodes of a multi-electrode implantable cardiac electrotherapy device for pacing, said method comprising:
selecting a first electrode or combination of electrodes as a first candidate to be used for pacing;
determining measurements comprising activation time ΔTact and activation recovery interval (ari) based on sensed cardiac electrical activity, for the first candidate;
selecting a second electrode or combination of electrodes as a second candidate to be used for pacing;
determining measurements comprising activation time ΔTact and activation recovery interval (ari) based on sensed cardiac electrical activity, for the second candidate;
comparing the measurements for the first and second candidates; and
identifying one of the first and second candidates for pacing based on the comparisons by identifying the candidate with at least one of a shortest activation time ΔTact and a smallest ari.
5. A method of identifying an electrode or combination of electrodes of a multi-electrode implantable cardiac electrotherapy device for pacing, said method comprising:
selecting a first electrode or combination of electrodes as a first candidate to be used for pacing based on a desired pacing type;
determining measurements comprising activation time ΔTact and activation recovery interval (ari) based on sensed cardiac electrical activity, for the first candidate;
selecting a second electrode or combination of electrodes as a second candidate to be used for pacing based on the desired pacing type;
determining measurements comprising activation time ΔTact and activation recovery interval (ari) based on sensed cardiac electrical activity, for the second candidate;
weighting a result of at least one of the comparison of the activation times ΔTact and the comparison of the aris based on the desired type of pacing;
comparing the measurements for the first and second candidates; and
identifying one of the first and second candidates for pacing based on the comparison.
2. The method of
3. The method of
delivering a pacing pulse to the candidate;
for each of a plurality of non-candidate electrodes:
sensing cardiac activity at the non-candidate electrode;
measuring the time between the delivery of the pacing pulse to the candidate and the sensing of cardiac activity at the non-candidate electrode;
comparing the measured times; and
selecting the largest measured time as the activation time ΔTact for the candidate electrode.
4. The method of
delivering a pacing pulse to the candidate;
for each of a plurality of non-candidate electrodes positioned in or on a ventricle:
sensing cardiac activity at the non-candidate electrode;
measuring the time between the delivery of the pacing pulse to the candidate and the end of recovery of the sensed cardiac activity at the non-candidate electrode;
for each of a plurality of non-candidate electrodes positioned in or on an atria:
sensing cardiac activity at the non-candidate electrode;
determining the time between the delivery of the pacing pulse to the candidate and the sensing of cardiac activity at the non-candidate electrode;
summing the determined time and a predetermined effective refractory period corresponding to the non-candidate electrode,
comparing the measured and summed times to each other; and
selecting the smallest of the measured and summed times as the ari for the candidate electrode.
6. The method of
when the desired type of pacing is cardiac resynchronization therapy, the activation times ΔTact result is weighted more heavily than the ari result; and
when the desired type of pacing is prevention type pacing, the ari result is weighted more heavily than the activation times ΔTact result.
|
The present invention relates to medical devices and methods of using such devices. More specifically, the present invention relates to implantable cardiac electrotherapy devices and methods of using such devices.
In a normal human heart, the sinus node, generally located near the junction of the superior vena cava and the right atrium, constitutes the primary natural pacemaker initiating rhythmic electrical excitation of the heart chambers. The cardiac impulse arising from the sinus node is transmitted to the two atrial chambers, causing a depolarization known as a P-wave and the resulting atrial chamber contractions. The excitation pulse is further transmitted to and through the ventricles via the atrioventricular (A-V) node and a ventricular conduction system causing a depolarization known as an R-wave and the resulting ventricular chamber contractions.
Disruption of this natural pacemaking and conduction system as a result of aging or disease may be successfully treated by artificial cardiac pacing using implantable cardiac electrotherapy devices, including pacemakers and implantable defibrillators, which deliver rhythmic electrical pulses or other anti-arrhythmia therapies to the heart at a desired energy and rate. One or more heart chambers may be electrically stimulated depending on the location and severity of the conduction disorder.
Cardiac pacemakers conventionally stimulate a heart chamber by applying current pulses to cardiac tissues via two electrodes, a cathode and an anode. Standard pacing leads are available in either of two configurations, unipolar leads or bipolar leads, depending on the arrangement of the electrodes of a particular lead. A unipolar pacing lead contains a single electrode, normally the cathode, which extends pervenously distal from the pacemaker in an insulating enclosure until it is adjacent to the tip of the lead where the insulation is terminated to provide for electrical contact of the cathode with the heart tissue. The anode provides a return path for the pacing electrical circuit. For a unipolar lead, the anode is the pacemaker case.
A bipolar lead contains two electrodes within an insulating sheath, an anode that extends distal from the pacemaker to a position adjacent to, but spaced from, the electrode tip, and a cathode that also extends distal from the pacemaker, but terminates a short distance distal of the anode, at the lead tip. The anode commonly takes the form of a ring having greater surface area than the cathode tip. An insulating barrier separates the cathode and anode of a bipolar lead. In current pacemakers, circuits for pacing and sensing, which determine tip, ring and case electrode connections, are provided. Thus, the pacemakers may be programmed for either bipolar or unipolar operation with respect to either sensing or pacing operations.
Systems and methods have been developed for determining various operating conditions for implantable cardiac electrotherapy devices. For example, electrode configurations may be determined for sensing and stimulating, cathode and anode assignments may be determined, and coupling intervals may be determined for precisely controlling the activation sequence of electrodes. Determining such operating conditions may be particularly suitable for programmable control systems of implantable cardiac devices.
Although technology for implantable cardiac devices has advanced to provide multiple electrodes that are available for pacing and/or sensing, developing ways to take advantage of such technology is ongoing. It would be beneficial to be able to determine a preferred or optimal pacing configuration for a device implanted in a patient, for example, to provide an efficient electrotherapy and/or to provide an electrotherapy that is less likely to result in arrhythmia.
Thus, there is a need in the art for a system for identifying an electrode or combination of electrodes for a preferred or optimal pacing configuration for a multi-electrode implantable cardiac electrotherapy device. There is also a need in the art for a method of identifying an electrode or combination of electrodes for a preferred or optimal pacing configuration for a multi-electrode implantable cardiac electrotherapy device.
The present invention contemplates identifying, selecting and/or using an electrode or combination of electrodes corresponding to a preferred or optimal pacing configuration. Specifically, embodiments of the invention contemplate using a conduction-based approach to identify, select and/or use an electrode or combination of electrodes for pacing. Such an approach may result in a fastest or optimal conduction across a region of cardiac tissue, resulting in an efficient application of electrotherapy. This may also provide improved contraction and/or hemodynamics.
The invention also contemplates using an activation recovery interval (ARI)-based approach to identify, select and/or use an electrode or combination of electrodes for pacing. Such an approach may result in a reduced vulnerability to developing arrhythmia from electrotherapy, resulting in a safer application of electrotherapy. Fractionated electrogram features may also be used to identify, select and/or use an electrode or combination of electrodes for pacing.
Embodiments of the invention also contemplate using a combined conduction-based and ARI-based approach to identify, select and/or use an electrode or combination of electrodes for pacing. Such an approach may allow a fastest or optimal conduction to be obtained without an undesirable or unacceptable susceptibility to arrhythmia. Such an approach may also provide systems and methods that are adaptable to a particular type of electrotherapy, such as resynchronization-type pacing or prevention-type pacing.
In general, the invention involves selecting a first electrode or combination of electrodes as a first candidate to be used for pacing and determining a measurement based on sensed cardiac electrical activity, for the first candidate. The invention further involves selecting a second electrode or combination of electrodes as a second candidate to be used for pacing and determining a measurement based on sensed cardiac electrical activity, for the second candidate. The measurements for the first and second candidates are compared and one of the first and second candidates is identified for pacing based on the comparison. As stated above, these measurements may be one or more of activation time ΔTact, activation recovery interval (ARI), a fractioned electrogram width, and a standard deviation of a fractioned electrogram feature
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. As will be realized, the invention is capable of modifications in various aspects, all without departing from the spirit and scope of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
The following description relates to embodiments presently contemplated for practicing the invention. This description is not to be taken in a limiting sense but is made merely for the purpose of describing the general principles of the invention. The scope of the invention should be ascertained with reference to the issued claims. In the description of the invention that follows, like numerals or reference designators will be used to refer to like parts or elements throughout.
Embodiments of the present invention are described in relation to a cardiac stimulation device capable of delivering precisely ordered stimulation pulses to multiple chambers of the heart, referred to herein as multi-chamber stimulation, or to multiple sites within a chamber of the heart, referred to herein as multi-site stimulation. As used herein, the shape of the stimulation pulses is not limited to an exact square or rectangular shape, but may assume any one of a plurality of shapes that is adequate for the delivery of an energy packet or stimulus.
The stimulation device is intended for use in patients suffering from hemodynamic dysfunction, which may or may not be accompanied by conduction disorders. Precisely controlled stimulation at multiple sites or in multiple chambers is provided to intentionally make use of the pacing function of the heart to improve cardiac hemodynamics by re-coordinating heart chamber contractions and/or preventing arrhythmogenic depolarizations from occurring. Thus, the cardiac stimulation device is capable of delivering at least low-voltage stimulation pulses to multiple stimulation sites for providing pacing therapy, and may include high-voltage stimulation shocks for providing cardioversion therapy and defibrillation therapy.
In one embodiment, the goal may be to identify, select and/or use one of the electrodes 1, 2, 3, 4 or a combination of two or more of the electrodes, i.e., candidate electrodes, for pacing such that a fastest conduction across the cardiac tissue is achieved. Fast conduction is likely to induce coherent and/or uniform contraction of the cardiac tissue, which may lead to improved hemodynamics. Thus, one embodiment provides a conduction-based approach for identifying an optimal pacing electrode or electrode combination.
Such an approach may selectively test individual candidates comprising one or more of the electrodes 1, 2, 3, 4 to determine an activation time ΔTact for each candidate. The activation time ΔTact for a particular candidate denotes the difference between the time of delivery of the pacing signal to cardiac tissue through the candidate electrode and the last (latest) activation sensed from one or more of the other, i.e., non-candidate, electrodes. The activation time ΔTact for the candidate thus corresponds to the largest conduction time—of all measured conduction times—between the candidate electrode and the non-candidate electrodes.
For example, electrodes 1 and 3 may be selected as candidates for pacing. To determine the activation time ΔTact for electrode 1, a pacing signal is applied to cardiac tissue through electrode 1 and activation times for each of the other electrodes 2, 3, 4 is determined based on the time that electrical cardiac activity is sensed at the electrode. The pacing signal is generated by a pulse generator of the cardiac stimulation device. The cardiac activations at each of the other electrodes 2, 3, 4 are sensed by either a bipolar or unipolar sensing configuration involving the electrode or in any known or hereafter developed manner, such as using one or more sensors capable of sensing an electrical impulse from each electrode 2, 3, 4.
Similarly, to determine the activation time ΔTact for the other candidate, electrode 3, a pacing signal is applied through electrode 3 and the last “activation” of the other electrodes 1, 2, 4 is determined.
A comparison is made between the activation times ΔTact of the candidates. Based on the comparison, one of the candidates is identified as being preferred or optimal for pacing. In the examples of
Although the foregoing description was in terms of single electrodes as candidates for pacing, it is understood that single electrodes and/or combinations of electrodes may be selected as candidates for pacing. For example, the present invention contemplates simultaneous multiple electrode pacing, as well as linear pacing from multiple electrodes, for example, as described in copending U.S. application Ser. No. 11/683,981, titled “Implantable Cardiac Stimulation Device Providing Multi-Site Pacing and Method,” filed Mar. 8, 2007, the entire disclosure of which is incorporated herein by reference. Further, although the foregoing description refers to epicardial electrodes, such an approach is equally applicable to endocardial electrodes.
The conduction-based approach described above may also be used in connection with a pacing device including multiple electrodes, one of which is designated for sensing only. In particular, the conduction-based approach described above may be applied to multiple electrodes placed for atrial pacing.
To sense left atrial and/or left ventricular cardiac signals and to provide left-chamber pacing therapy, the stimulation device 10 may be coupled to a “coronary sinus” lead 24 configured to be placed in the “coronary sinus region” via the coronary sinus so as to place a distal electrode adjacent to the left ventricle and additional electrode(s) adjacent to the left atrium. As used herein, the phrase “coronary sinus region” refers to the vasculature of the left ventricle, including any portion of the coronary sinus, great cardiac vein, left marginal vein, left posterior ventricular vein, middle cardiac vein, and/or small cardiac vein or any other cardiac vein accessible by the coronary sinus. It should be understood that the lead 24 could also be an epicardial lead placed at the time of thoracotomy or thorascopy.
Accordingly, the coronary sinus lead 24 may be configured to receive atrial and/or ventricular cardiac signals and to deliver left ventricular pacing therapy using at least a left ventricular tip electrode 26, left atrial pacing therapy using at least a left atrial ring electrode 27, and shocking therapy using at least a left atrial coil electrode 28. In addition to the left ventricular tip electrode 26, other left ventricle electrodes 26a, 26b, 26c, 26d may be included. For a more detailed description of an exemplary coronary sinus lead, refer to U.S. Pat. No. 5,466,254, titled “Coronary Sinus Lead with Atrial Sensing Capability” (Helland), the entire disclosures of which are incorporated herein by reference.
The stimulation device 10 is also shown in electrical communication with the patient's heart 12 via an implantable right ventricular lead 30 including, in this embodiment, a right ventricular tip electrode 32, a right ventricular ring electrode 34, a right ventricular (RV) coil electrode 36, and an SVC coil electrode 38. Typically, the right ventricular lead 30 is transvenously inserted into the heart 12 so as to place the right ventricular tip electrode 32 in the right ventricular apex so that the RV coil electrode 36 will be positioned in the right ventricle and the SVC coil electrode 38 will be positioned in the superior vena cava. Accordingly, the right ventricular lead 30 may be configured to receive cardiac signals, and deliver stimulation in the form of pacing and shock therapy to the right ventricle.
In one embodiment, the goal may be to identify, select and/or use one of the left ventricle electrodes 26a, 26b, 26c, 26d for pacing such that a fastest conduction across the cardiac tissue, specifically to the right ventricle, is achieved. In this case, any or all of the electrodes 32, 34, 36, 38 of the right ventricular lead 30 may be used as non-candidate electrodes to determine the activation time ΔTact for each candidate electrode 26a, 26b, 26c, 26d.
As described above with respect to
Once the activation times ΔTact for each of the candidate electrodes has been measured, a comparison may be made between the activation times ΔTact of the candidates. Based on the comparison, one of the candidates may be identified as being preferred or optimal for pacing.
Although the foregoing description is in terms of single electrodes as candidates for pacing, it is understood that single electrodes and/or combinations of electrodes may be selected as candidates for pacing. For example, when four pacing electrodes 26a, 26b, 26c and 26d are available, up to ten possible combinations of electrode-pairing exist that may be evaluated as candidates for multiple-electrode pacing. These electrode-combinations include: 26a/26b, 26a/26c, 26a/26d, 26b/26c, 26b/26d, 26c/26d, 26a/26b/26c, 26a/26b/26d, 26a/26c/26d and 26b/26c/26d. Any or all of the combinations of electrode pairing may be evaluated, either with or without evaluation of single electrode candidates.
Alternatively or additionally, embodiments of the invention contemplate using an activation recovery interval (ARI)-based approach to identify, select and/or use an electrode or combination of electrodes for pacing. Such an approach may result in a reduced vulnerability to developing arrhythmia from electrotherapy, resulting in a safer application of electrotherapy.
Referring back to
Such an approach may selectively test individual candidates including one or more of the electrodes 1, 2, 3, 4 to determine an ARI for each candidate. The ARI for a particular candidate corresponds to the difference between the time of delivery of the pacing signal to cardiac tissue through the candidate electrode and the earliest end-of-recovery sensed from one or more of the other electrodes. The ARI for the candidate thus corresponds to the smallest ARI—of all measured ARIs—between the candidate electrode and the non-candidate electrodes.
As shown in
Regarding atrial electrodes, because the recovery phase for the atrium is usually hidden in the far-field R wave, detection of atrial cardiac activity and corresponding measurement of ERPs for atrial electrodes may be quite difficult. Thus, ERPs for atrial electrodes may be determined or measured beforehand, for example, during implant. Any suitable technique may be used to determine ERPs, whether known or hereafter developed, for example, such as described in “Methods for Determining the Refractory Period and Excitable Gap During Persistent Atrial Fibrillation in the Goat,” M. Duytschaever et al., Circulation 2001; 104:957-962, which is incorporated by reference herein in its entirety. The ARI measurement for atrial non-candidate electrodes may thus be determined by measuring the activation time for the atrial non-candidate electrode and adding it to the predetermined ERP for that electrode.
Regarding ventricular electrodes, because the recovery phase for the ventricle is more prominent, as illustrated in
Further regarding ventricular electrodes, rather than directly measuring the ARI, the ERP and the activation time ΔTact may be determined or measured for each non-candidate electrode. The activation time ΔTact and the ERP may be determined using any suitable technique, whether known or hereafter developed, for example, such as described in connection with the electrophysical studies in “Novel Electrophysical Parameter of Dispersion of Atrial Repolarization Comparison of Different Atrial Pacing Methods,” M. Ogawa, et. al., Journal of Cardiovascular Electrophysiology (February 2002); 13:110-117, which is incorporated by reference herein in its entirety. Activation recovery intervals may also be determined or measured as described in U.S. Pat. No. 7,107,093, the entire disclosure of which is incorporated herein by reference.
Once the ARI for each candidate electrode has been obtained, a comparison may be made between the ARIs of the candidates. Based on the comparison, one of the candidates may be identified as being preferred or optimal for pacing based on a smallest dispersion of ARI. Thus, the candidate electrode or electrode combination with the smallest ARI dispersion may be identified as the electrode or electrode combination to select and/or use for pacing.
It should be understood that the ARI dispersion may be measured in terms of standard deviation. Thus, the candidate electrode(s) with the smallest standard deviation of ARI may be identified as the electrode(s) to select and/or use for pacing.
Although the foregoing description is in terms of single electrodes as candidates for pacing, it should be understood that single electrodes and/or combinations of electrodes may be selected as candidates for pacing. The ARI-based approach described above may also be used in connection with a pacing device including multiple electrodes, one of which is designated for sensing only, as discussed above with respect to
Embodiments of the invention also contemplate using a combined approach, i.e., using both activation times ΔTact and ARI dispersions, to identify, select and/or use an electrode or combination of electrodes for pacing. Such an approach may desirably combine the results obtained by the conduction-based approach and the ARI-based approach individually. For example, such a combined approach may take into account both hemodynamics and arrhythmia susceptibility to identify a preferred or optimal pacing configuration.
Using only a conduction-based approach may identify an electrode or electrodes that, while providing desirable conduction and hemodynamics, yields a largest ARI dispersion among the candidate electrodes. Thus, while efficiency/performance of pacing using the identified electrode(s) may be desirable, the relatively large or increased likelihood of developing arrhythmia may be unacceptable. Using a combined approach may avoid such an undesirable result.
For a combined approach, the activation times ΔTact and ARI dispersions may be obtained and compared as discussed above. The identification of the electrode(s) to be used for pacing may then be based on the results of both comparisons.
For example, the results from one or both comparisons may be weighted to allow the results from the different comparisons to be combined into a meaningful result and/or to create a particular preference, such as for better hemodynamics or for reduced susceptibility of arrhythmia. Such weighting factors may be determined empirically, and may be set based on a desired type of pacing. For example, better hemodynamics may be more important for cardiac resynchronization therapy (CRT) pacing, and thus the result of the conduction-based comparison may be more heavily weighted. For prevention-type pacing, reduced susceptibility of arrhythmia may be more important, and thus the result of the ARI dispersion comparison may be more heavily weighted.
It should be understood that the foregoing approaches may be applied to all types of pacing, including antitachycardia pacing (ATP).
Alternatively or additionally to the approaches described above, an optimal electrode for pacing may be selected based on the presence of a fractionated electrogram. As illustrated in
The stimulation device 10 includes a housing 50 which may be programmably selected to act as a return electrode for unipolar pacing and sensing electrode configurations. The housing 50 includes various terminals 52 for electrically connecting to various electrodes, such as shown in
The stimulation device 10 includes a controller 60 that controls various modes of stimulation therapy and the identification of a preferred or optimum pacing configuration, as discussed herein. The details of the design and operation of the controller 60 are not critical to the present invention. Rather, any suitable controller 60 may be used that carries out the functions described herein.
The controller 60 includes a microprocessor, or equivalent control circuitry, configured to execute various functions and to control other elements in accordance with the desired operation of the device 10. The controller 60 may include logic and timing circuitry, state machine circuitry, I/O circuitry, and any other appropriate circuitry. The controller 60 is capable of processing and/or monitoring input signals (data) as controlled by a program code stored in a designated block of memory 94.
The controller 60 includes a comparison circuit 62 that is configured to carry out the comparisons of activation times ΔTact and ARI dispersions as discussed herein. As discussed further below, data from the electrodes may be received by the controller 60, processed as desired and provided to the comparison circuit 62.
As shown in
An atrial sensing circuit 82 and a ventricular sensing circuit 84 are selectively coupled to the leads and electrodes, through the switch bank 74, for sensing the presence of cardiac activity. To sense events occurring within each chamber or at each stimulation site independently, the atrial and ventricular sensing circuits 82 and 84 may include dedicated independent sense amplifiers associated with each stimulation site within the heart 12. Each of the atrial sensing circuit 82 and the ventricular sensing circuit 84 may include a discriminator, which is a circuit that senses and can indicate or discriminate the origin of a cardiac signal.
The inputs to each sense amplifier 82, 84 may be programmable and may be selected, for example, by the controller 60, in any combination of available electrode terminals 52 to provide independent identification of inputs from the various electrodes. Unique sensing circuitry may be used for each electrode to allow discrimination of a detected event. Each of the atrial sensing circuit 82 or the ventricular sensing circuit 84 may employ one or more low power, precision amplifiers with programmable gain and/or automatic gain control, bandpass filtering, and a threshold detection circuit, to selectively sense the cardiac signal of interest. The sensing amplifiers 82, 84 receive control signals over signal lines 86, 88 from the controller 60 for the purposes of controlling the gain, threshold, polarization charge removal circuitry (not shown), and the timing of any block circuitry (not shown) coupled to the inputs of the sensing amplifiers, as is known in the art.
The outputs of the atrial and ventricular sensing circuits 82 and 84 may be connected to the controller 60 for triggering or inhibiting the atrial and ventricular pulse generators 70 and 72, respectively, as well as for providing data from the electrodes to determine a preferred or optimal pacing configuration in accordance with the present invention. Alternatively or additionally, data from the electrodes may be provided to the controller 60 by one or more physiologic sensors 108 suitably positioned on or in the heart, or by a suitable measuring circuit 112.
In carrying out the approaches described herein, the controller 60 selects a plurality of individual electrodes and/or electrode combinations as candidates for pacing. The controller 60 controls the pulse generator 70 to selectively output a pacing pulse to one of the candidate electrodes or candidate electrode combinations. The controller 60 also controls the inputs to one or more of the sensing circuits 82, 84, the physiologic sensor 108 and/or the measuring circuit 112 via the electrode configuration switch 74 to obtain various activation time ΔTact, ARI and/or fractionated electrogram measurements based on the activity sensed at one or more of non-candidate electrodes in response to the pacing pulse. The process of testing each candidate electrode or electrode combination may be repeated until all have been tested before the activation time ΔTact, ARI and/or fractionated electrogram data for the candidate electrode is sent to the comparison circuit 62 for analysis. Alternatively, the activation time ΔTact, ARI and/or fractionated electrogram data of successively tested candidates may be compared by the comparison circuit 62 to reduce the amount of data stored in the memory 94 for later comparison.
In either case, the comparison circuit 62 may compare the activation time ΔTact, ARI and/or fractionated electrogram data obtained from testing the candidate electrodes and/or electrode combinations, and provide the results to the controller 60. When the data of successively tested candidates is compared, the controller 60 may use each successive comparison result to methodically eliminate the less desirable candidate and finally identify an electrode or electrode combination for pacing. Otherwise, the controller 60 may simply use an overall result from the comparison circuit 62 to identify an electrode or electrode combination for pacing.
It should be understood that the controller 60 may perform one or more intermediate steps to support the various comparisons made by the comparison circuit 62. For example, when a combined conduction-based and ARI-based approach is used, the controller 60 may provide the weighting for comparison.
In general, the various components illustrated in
With reference to
A second electrode or electrode combination may then be selected as a second candidate to be used for pacing [block 300]. Again, a candidate activation time ΔTact and/or candidate ARI may be determined for the second candidate [block 400].
Next, the activation times ΔTact for the first and second candidates may be compared [block 500]. Alternatively or additionally, the ARI for the first and second candidates may be compared [block 600]. Based on the comparisons, with or without an additional step of weighting as discussed above, one of the first and second candidates may be identified as a preferred or optimum configuration for pacing [block 700]. Once the process is complete, the identified electrode or electrode combination may be used to execute a pacing therapy as necessary or desired.
Although not shown for the sake of simplicity, it should be understood that suitable loops may be included in the illustrative flowchart of
Further, it should be understood that the foregoing methods may be used to periodically monitor and/or update optimal electrode selection. For example, the device may be configured to periodically monitor the electrode selection. Any suitable period may be used, such as monthly, weekly, etc. Alternatively, the device may be configured to continuously monitor the electrode selection.
In some embodiments, the device may implement one or more of the foregoing methods of selecting one or more electrodes for pacing upon detection of a preset cardiac parameter, for example. Alternatively or additionally, the device may periodically (e.g., monthly) implement one or more of the methods. In such a manner, the device may periodically “test” whether the current optimal pacing electrode may be replaced by another available electrode.
Although the present invention has been described with reference to preferred embodiments, persons skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
Bornzin, Gene A., Gill, Jong, Ryu, Kyungmoo, Karicherla, Annapurna
Patent | Priority | Assignee | Title |
10064567, | Apr 30 2013 | Medtronic, Inc | Systems, methods, and interfaces for identifying optimal electrical vectors |
10206601, | Dec 09 2013 | Medtronic, Inc | Noninvasive cardiac therapy evaluation |
10251555, | Jun 12 2013 | Medtronic, Inc | Implantable electrode location selection |
10368766, | Dec 09 2013 | Medtronic, Inc. | Bioelectric sensor device and methods |
10369368, | Dec 07 2009 | Pacesetter, Inc. | Optimal pacing configuration via ventricular conduction delays |
10433746, | Dec 22 2017 | MYOCHRON, INC | Systems and methods for anterior and posterior electrode signal analysis |
10492705, | Dec 22 2017 | MYOCHRON, INC | Anterior and posterior electrode signals |
10532213, | Mar 03 2017 | Medtronic, Inc.; Medtronic, Inc | Criteria for determination of local tissue latency near pacing electrode |
10617318, | Feb 27 2018 | Medtronic, Inc.; Medtronic, Inc | Mapping electrical activity on a model heart |
10668290, | Mar 01 2018 | Medtronic, Inc.; Medtronic, Inc | Delivery of pacing therapy by a cardiac pacing device |
10773085, | Mar 15 2017 | Boston Scientific Scimed, Inc | QRS offset and onset determination |
10780279, | Feb 26 2016 | Medtronic, Inc. | Methods and systems of optimizing right ventricular only pacing for patients with respect to an atrial event and left ventricular event |
10780281, | Mar 23 2018 | Medtronic, Inc. | Evaluation of ventricle from atrium pacing therapy |
10786167, | Dec 22 2017 | Medtronic, Inc | Ectopic beat-compensated electrical heterogeneity information |
10799703, | Dec 22 2017 | Medtronic, Inc | Evaluation of his bundle pacing therapy |
10918863, | Jul 28 2017 | Medtronic, Inc | Generating activation times |
10918870, | Mar 07 2018 | Medtronic, Inc.; Medtronic, Inc | Atrial lead placement for treatment of atrial dyssynchrony |
10940321, | Jun 01 2018 | Medtronic, Inc. | Systems, methods, and interfaces for use in cardiac evaluation |
11027135, | May 03 2011 | Medtronic, Inc. | Assessing intra-cardiac activation patterns |
11219769, | Feb 26 2016 | Medtronic, Inc. | Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing |
11253178, | Jan 29 2015 | Medtronic, Inc.; Medtronic, Inc | Noninvasive assessment of cardiac resynchronization therapy |
11285312, | Mar 29 2018 | Medtronic, Inc | Left ventricular assist device adjustment and evaluation |
11304641, | Jun 01 2018 | Medtronic, Inc. | Systems, methods, and interfaces for use in cardiac evaluation |
11419539, | Dec 22 2017 | MYOCHRON, INC | QRS onset and offset times and cycle selection using anterior and posterior electrode signals |
11456062, | Dec 09 2013 | Medtronic, Inc. | Noninvasive cardiac therapy evaluation |
11471678, | Jul 28 2017 | Medtronic, Inc | Cardiac cycle selection |
11497431, | Oct 09 2019 | Medtronic, Inc. | Systems and methods for configuring cardiac therapy |
11547858, | Mar 29 2019 | Medtronic, Inc | Systems, methods, and devices for adaptive cardiac therapy |
11642533, | Nov 04 2019 | Medtronic, Inc.; Medtronic, Inc | Systems and methods for evaluating cardiac therapy |
11648406, | Apr 30 2013 | Medtronic, Inc. | Systems, methods, and interfaces for identifying effective electrodes |
11697025, | Mar 29 2019 | Medtronic, Inc | Cardiac conduction system capture |
11801390, | Jun 06 2018 | Medtronic, Inc.; Medtronic, Inc | Identification and adjustment for loss of effective cardiac resynchronization therapy |
11813464, | Jul 31 2020 | Medtronic, Inc. | Cardiac conduction system evaluation |
12133984, | May 03 2011 | Medtronic, Inc. | Assessing intra-cardiac activation patterns |
8548587, | Apr 19 2011 | Pacesetter, Inc | Devices, systems and methods for characterizing a tachycardia and/or selecting treatment for a tachycardia using results of a fractionation analysis |
8615298, | Feb 17 2012 | Medtronic, Inc.; Medtronic, Inc | Criteria for optimal electrical resynchronization derived from multipolar leads or multiple electrodes during biventricular pacing |
8620433, | Feb 17 2012 | Medtronic, Inc.; Medtronic, Inc | Criteria for optimal electrical resynchronization derived from multipolar leads or multiple electrodes during biventricular pacing |
8694099, | Feb 17 2012 | Medtronic, Inc; Medronic, Inc. | Criteria for optimal electrical resynchronization derived from multipolar leads or multiple electrodes during biventricular pacing |
8768465, | May 04 2012 | Medtronic, Inc.; Medtronic, Inc | Criteria for optimal electrical resynchronization derived from multipolar leads or multiple electrodes during biventricular pacing |
8798731, | Jul 29 2011 | Pacesetter, Inc | Devices, systems and methods to perform arrhythmia discrimination based on the atrial and ventricular activation times |
8929984, | Feb 21 2013 | Medtronic, Inc.; Medtronic, Inc | Criteria for optimal electrical resynchronization during fusion pacing |
8996111, | Apr 27 2012 | Medtronic, Inc.; Medtronic, Inc | Lead recognition for an implantable medical system |
9002453, | Jul 29 2011 | Pacesetter, Inc | Devices, systems and methods to perform arrhythmia discrimination based on R-R interval stability corresponding to a plurality of ventricular regions |
9044620, | Jul 29 2011 | Pacesetter, Inc. | Devices, systems and methods to perform arrhythmia discrimination based on the atrial and ventricular activation times |
9079037, | Apr 27 2012 | Medtronic, Inc.; Medtronic, Inc | Fault tolerant implantable medical system |
9155897, | May 04 2012 | Medtronic, Inc | Criteria for optimal electrical resynchronization during biventricular pacing |
9254392, | Dec 31 2013 | Medtronic, Inc | Anodal capture detection |
9265951, | Feb 12 2010 | THE BRIGHAM AND WOMEN S HOSPITAL | System and method for automated adjustment of cardiac resynchronization therapy control parameters |
9265954, | Jul 26 2013 | Medtronic, Inc.; Medtronic, Inc | Method and system for improved estimation of time of left ventricular pacing with respect to intrinsic right ventricular activation in cardiac resynchronization therapy |
9265955, | Jul 26 2013 | Medtronic, Inc.; Medtronic, Inc | Method and system for improved estimation of time of left ventricular pacing with respect to intrinsic right ventricular activation in cardiac resynchronization therapy |
9272148, | Jul 23 2013 | Medtronic, Inc.; Medtronic, Inc | Combination of feedback on mechanical and electrical resynchronization to select therapy parameters |
9278219, | Mar 15 2013 | Medtronic, Inc.; Medtronic, Inc | Closed loop optimization of control parameters during cardiac pacing |
9278220, | Jul 23 2013 | Medtronic, Inc.; Medtronic, Inc | Identification of healthy versus unhealthy substrate for pacing from a multipolar lead |
9282907, | Jul 23 2013 | Medtronic, Inc.; Medtronic, Inc | Identification of healthy versus unhealthy substrate for pacing from a multipolar lead |
9320446, | Dec 09 2013 | Medtronic, Inc | Bioelectric sensor device and methods |
9381363, | Dec 07 2009 | Pacesetter, Inc. | Optimal pacing configuration via ventricular conduction delays |
9474457, | Jun 12 2013 | Medtronic, Inc.; Medtronic, Inc | Metrics of electrical dyssynchrony and electrical activation patterns from surface ECG electrodes |
9486151, | Jun 12 2013 | Medtronic, Inc.; Medtronic, Inc | Metrics of electrical dyssynchrony and electrical activation patterns from surface ECG electrodes |
9510763, | May 03 2011 | Medtronic, Inc.; Medtronic, Inc | Assessing intra-cardiac activation patterns and electrical dyssynchrony |
9511234, | May 04 2012 | Medtronic, Inc. | Criteria for optimal electrical resynchronization derived from multipolar leads or multiple electrodes during biventricular pacing |
9554717, | Jul 29 2011 | Pacesetter, Inc | Devices, systems and methods to monitor and treat heart failure (HF) |
9586050, | Aug 15 2014 | Medtronic, Inc. | Systems and methods for configuration of atrioventricular interval |
9586052, | Aug 15 2014 | Medtronic, Inc | Systems and methods for evaluating cardiac therapy |
9591982, | Jul 31 2014 | Medtronic, Inc. | Systems and methods for evaluating cardiac therapy |
9604064, | Feb 21 2013 | Medtronic, Inc.; Medtronic, Inc | Criteria for optimal electrical resynchronization during fusion pacing |
9610447, | Mar 30 2012 | Pacesetter, Inc | Systems and methods for selecting pacing vectors based on site of latest activation for use with implantable cardiac rhythm management devices |
9649497, | Mar 15 2013 | Medtronic, Inc. | Closed loop optimization of control parameters during cardiac pacing |
9700728, | Jul 23 2013 | Medtronic, Inc. | Combination of feedback on mechanical and electrical resynchronization to select therapy parameters |
9700729, | May 04 2012 | Medtronic, Inc. | Criteria for optimal electrical resynchronization during biventricular pacing |
9707400, | Aug 15 2014 | Medtronic, Inc. | Systems, methods, and interfaces for configuring cardiac therapy |
9764143, | Aug 15 2014 | Medtronic, Inc. | Systems and methods for configuration of interventricular interval |
9776009, | Mar 20 2014 | Medtronic, Inc.; Medtronic, Inc | Non-invasive detection of phrenic nerve stimulation |
9877789, | Jun 12 2013 | Medtronic, Inc | Implantable electrode location selection |
9924884, | Apr 30 2013 | Medtronic, Inc | Systems, methods, and interfaces for identifying effective electrodes |
9931048, | Apr 30 2013 | Medtronic, Inc | Systems, methods, and interfaces for identifying effective electrodes |
9962097, | May 03 2011 | Medtronic, Inc. | Assessing intra-cardiac activation patterns and electrical dyssynchrony |
9974457, | May 03 2011 | Medtronic, Inc. | Assessing intra-cardiac activation patterns |
9974964, | Apr 27 2012 | Medtronic, Inc. | Fault tolerant implantable medical system |
9986928, | Dec 09 2013 | Medtronic, Inc | Noninvasive cardiac therapy evaluation |
9993172, | Dec 09 2013 | Medtronic, Inc | Noninvasive cardiac therapy evaluation |
ER2533, |
Patent | Priority | Assignee | Title |
5466254, | Sep 22 1993 | Pacesetter, Inc | Coronary sinus lead with atrial sensing capability |
6456876, | Feb 28 2000 | Pacesetter, Inc.; Pacesetter, Inc | Dual-chamber implantable cardiac stimulation system and device with selectable arrhythmia termination electrode configurations and method |
6473645, | Jul 11 2001 | Pacesetter, Inc. | System and method for programmably controlling electrode activation sequence in a multi-site cardiac stimulation device |
6477417, | Apr 12 2001 | Pacesetter, Inc. | System and method for automatically selecting electrode polarity during sensing and stimulation |
6606516, | Apr 12 2001 | Rapiscan Systems, Inc | System and method for programmably controlling stimulation electrode configurations and activation sequence in a multi-site cardiac stimulation device |
6909916, | Dec 20 2001 | Cardiac Pacemakers, Inc | Cardiac rhythm management system with arrhythmia classification and electrode selection |
6978178, | Apr 30 2002 | Medtronic, Inc | Method and apparatus for selecting an optimal electrode configuration of a medical electrical lead having a multiple electrode array |
7020523, | Apr 16 2002 | Pacesetter, Inc. | Methods and systems for automatically switching electrode configurations |
7107093, | Apr 29 2003 | Medtronic, Inc.; MEDTRONICS, INC | Use of activation and recovery times and dispersions to monitor heart failure status and arrhythmia risk |
7239913, | May 23 2001 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system selecting between multiple same-chamber electrodes for delivering cardiac therapy |
7647108, | Sep 30 2004 | Cardiac Pacemakers, Inc.; Cardiac Pacemakers, Inc | Methods and systems for selection of cardiac pacing electrode configurations |
20020151935, | |||
20020193834, | |||
20040102812, | |||
20040106958, | |||
20050038478, | |||
20090054946, | |||
WO2006105474, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Sep 05 2007 | KARICHERLA, ANNAPURNA | Pacesetter, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 019793 | /0038 | |
Sep 05 2007 | RYU, KYUNGMOO | Pacesetter, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 019793 | /0038 | |
Sep 05 2007 | BORNZIN, GENE A | Pacesetter, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 019793 | /0038 | |
Sep 06 2007 | Pacesetter, Inc. | (assignment on the face of the patent) | / | |||
Sep 06 2007 | GILL, JONG | Pacesetter, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 019793 | /0038 |
Date | Maintenance Fee Events |
Nov 07 2014 | REM: Maintenance Fee Reminder Mailed. |
Feb 10 2015 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Feb 10 2015 | M1554: Surcharge for Late Payment, Large Entity. |
Aug 21 2018 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Nov 14 2022 | REM: Maintenance Fee Reminder Mailed. |
May 01 2023 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Mar 29 2014 | 4 years fee payment window open |
Sep 29 2014 | 6 months grace period start (w surcharge) |
Mar 29 2015 | patent expiry (for year 4) |
Mar 29 2017 | 2 years to revive unintentionally abandoned end. (for year 4) |
Mar 29 2018 | 8 years fee payment window open |
Sep 29 2018 | 6 months grace period start (w surcharge) |
Mar 29 2019 | patent expiry (for year 8) |
Mar 29 2021 | 2 years to revive unintentionally abandoned end. (for year 8) |
Mar 29 2022 | 12 years fee payment window open |
Sep 29 2022 | 6 months grace period start (w surcharge) |
Mar 29 2023 | patent expiry (for year 12) |
Mar 29 2025 | 2 years to revive unintentionally abandoned end. (for year 12) |